<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31292991</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1096-8652</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>94</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>American journal of hematology</Title>
          <ISOAbbreviation>Am J Hematol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Evans syndrome in adults - incidence, prevalence, and survival in a nationwide cohort.</ArticleTitle>
        <Pagination>
          <StartPage>1081</StartPage>
          <EndPage>1090</EndPage>
          <MedlinePgn>1081-1090</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/ajh.25574</ELocationID>
        <Abstract>
          <AbstractText>Patients with Evans syndrome have both immune thrombocytopenia and autoimmune hemolytic anemia, but little is known about the epidemiology of this rare syndrome. Evans syndrome can be primary or secondary. This nationwide retrospective study linked health registries to identify 242 patients with Evans syndrome in Denmark in 1977-2017. For comparison, we identified three age-matched and sex-matched cohorts of patients with only immune thrombocytopenia or only autoimmune hemolytic anemia, and a general population cohort. The Evans syndrome cohort had a mean age of 58.5 years at diagnosis, 51.2% were women, and 27.3% were classified as secondary Evans syndrome. The annual Evans syndrome incidence and prevalence rose significantly during the study period, to 1.8 per million person-years and 21.3 per million persons, respectively, in 2016. The median survival with Evans syndrome was 7.2 years (primary Evans syndrome: 10.9 years; secondary Evans syndrome: 1.7 years). Secondary Evans syndrome was associated with higher mortality rates than any of the other cohorts, with a 5-year survival of 38%. Among patients with Evans syndrome, the prevailing causes of death were bleeding, infections, and hematological cancer. In conclusion, we found that both primary and secondary Evans syndrome conferred a poor prognosis. Lethal complications probably derive primarily from manifestations of underlying autoimmune hemolytic anemia and immune thrombocytopenia. Our findings suggested that suspicion of Evans syndrome should prompt vigilant clinical follow-up. International collaborations are warranted to advance our knowledge of optimal management of this rare disease.</AbstractText>
          <CopyrightInformation>© 2019 Wiley Periodicals, Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hansen</LastName>
            <ForeName>Dennis Lund</ForeName>
            <Initials>DL</Initials>
            <Identifier Source="ORCID">0000-0002-4478-1297</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, Odense University Hospital, Odense, Denmark.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Research, University of Southern Denmark, Odense, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Möller</LastName>
            <ForeName>Sören</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0003-0858-4269</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Research, University of Southern Denmark, Odense, Denmark.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>OPEN, Odense University Hospital, Odense, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Andersen</LastName>
            <ForeName>Kjeld</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0003-0456-5634</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Research, University of Southern Denmark, Odense, Denmark.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry - Odense, Region of Southern Denmark, Odense, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gaist</LastName>
            <ForeName>David</ForeName>
            <Initials>D</Initials>
            <Identifier Source="ORCID">0000-0001-5205-7007</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Research, University of Southern Denmark, Odense, Denmark.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Neurology Research Unit, Department of Neurology, Odense University Hospital, Odense, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Frederiksen</LastName>
            <ForeName>Henrik</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0001-8905-0220</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, Odense University Hospital, Odense, Denmark.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Research, University of Southern Denmark, Odense, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>17-L-0334</GrantID>
            <Agency>Alexion Pharma Nordic AB, The A. P. Møller and Chastine Mc-Kinney Møller Foundation</Agency>
            <Country>International</Country>
          </Grant>
          <Grant>
            <GrantID>16/13496</GrantID>
            <Agency>Region of Southern Denmark</Agency>
            <Country>International</Country>
          </Grant>
          <Grant>
            <GrantID>SDUSF-2015-202-(459)</GrantID>
            <Agency>University of Southern Denmark</Agency>
            <Country>International</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>08</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Am J Hematol</MedlineTA>
        <NlmUniqueID>7610369</NlmUniqueID>
        <ISSNLinking>0361-8609</ISSNLinking>
      </MedlineJournalInfo>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C536380">Evans Syndrome</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000744" MajorTopicYN="N">Anemia, Hemolytic, Autoimmune</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003718" MajorTopicYN="N" Type="Geographic">Denmark</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019337" MajorTopicYN="N">Hematologic Neoplasms</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007239" MajorTopicYN="N">Infections</DescriptorName>
          <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016553" MajorTopicYN="N">Purpura, Thrombocytopenic, Idiopathic</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013156" MajorTopicYN="N">Splenectomy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013921" MajorTopicYN="N">Thrombocytopenia</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>6</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>7</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>7</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>7</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>7</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31292991</ArticleId>
        <ArticleId IdType="doi">10.1002/ajh.25574</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Evans RS, Takahashi K, Duane RT, Payne R, Liu C. Primary thrombocytopenic purpura and acquired hemolytic anemia; evidence for a common etiology. AMA Arch Intern Med. 1951;87(1):48-65.</Citation>
        </Reference>
        <Reference>
          <Citation>Jaime-Perez JC, Aguilar-Calderon PE, Salazar-Cavazos L, Gomez-Almaguer D. Evans syndrome: clinical perspectives, biological insights and treatment modalities. J Blood Med. 2018;9:171-184.</Citation>
        </Reference>
        <Reference>
          <Citation>Aladjidi N, Fernandes H, Leblanc T, et al. Evans syndrome in children: long-term outcome in a prospective French national observational cohort. Front Pediatr. 2015;3:79.</Citation>
        </Reference>
        <Reference>
          <Citation>Aladjidi N, Leverger G, Leblanc T, et al. New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children. Haematologica. 2011;96(5):655-663.</Citation>
        </Reference>
        <Reference>
          <Citation>Audia S, Bach B, Samson M, et al. Venous thromboembolic events during warm autoimmune hemolytic anemia. PLoS One. 2018;13(11):e0207218.</Citation>
        </Reference>
        <Reference>
          <Citation>Barcellini W, Fattizzo B, Zaninoni A, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood. 2014;124(19):2930-2936.</Citation>
        </Reference>
        <Reference>
          <Citation>Ungprasert P, Tanratana P, Srivali N. Autoimmune hemolytic anemia and venous thromboembolism: a systematic review and meta-analysis. Thromb Res. 2015;136(5):1013-1017.</Citation>
        </Reference>
        <Reference>
          <Citation>Ruggeri M, Rodeghiero F. Thrombotic risk in patients with immune haemolytic anaemia. Br J Haematol. 2016;172(1):144-146.</Citation>
        </Reference>
        <Reference>
          <Citation>Frederiksen H, Maegbaek ML, Norgaard M. Twenty-year mortality of adult patients with primary immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol. 2014;166(2):260-267.</Citation>
        </Reference>
        <Reference>
          <Citation>Chandan JS, Thomas T, Lee S, et al. The association between idiopathic thrombocytopenic purpura and cardiovascular disease: a retrospective cohort study. J Thromb Haemost. 2018;16(3):474-480.</Citation>
        </Reference>
        <Reference>
          <Citation>Enger C, Bennett D, Forssen U, Fogarty PF, McAfee AT. Comorbidities in patients with persistent or chronic immune thrombocytopenia. Int J Hematol. 2010;92(2):289-295.</Citation>
        </Reference>
        <Reference>
          <Citation>Michel M, Chanet V, Dechartres A, et al. The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood. 2009;114(15):3167-3172.</Citation>
        </Reference>
        <Reference>
          <Citation>Barcellini W, Fattizzo B, Zaninoni A, Nesa F, Zanella A, Cortelezzi A. Lessons from very severe, refractory and fatal primary autoimmune haemolytic anaemias. Haematologica. 2015;100:781.</Citation>
        </Reference>
        <Reference>
          <Citation>Norton A, Roberts I. Management of Evans syndrome. Br J Haematol. 2006;132(2):125-137.</Citation>
        </Reference>
        <Reference>
          <Citation>Savasan S, Warrier I, Ravindranath Y. The spectrum of Evans' syndrome. Arch Dis Child. 1997;77(3):245-248.</Citation>
        </Reference>
        <Reference>
          <Citation>Baek SW, Lee MW, Ryu HW, et al. Clinical features and outcomes of autoimmune hemolytic anemia: a retrospective analysis of 32 cases. Korean J Hematol. 2011;46(2):111-117.</Citation>
        </Reference>
        <Reference>
          <Citation>Ng SC. Evans syndrome - a report on 12 patients. Clin Lab Haematol. 1992;14(3):189-193.</Citation>
        </Reference>
        <Reference>
          <Citation>Prabhu R, Bhaskaran R, Shenoy V, G R, Sidharthan N. Clinical characteristics and treatment outcomes of primary autoimmune hemolytic anemia: a single center study from South India. Blood Res. 2016;51(2):88-94.</Citation>
        </Reference>
        <Reference>
          <Citation>Lynge E, Sandegaard JL, Rebolj M. The Danish national patient register. Scand J Public Health. 2011;39(7 Suppl):30-33.</Citation>
        </Reference>
        <Reference>
          <Citation>Schmidt M, Pedersen L, Sorensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541-549.</Citation>
        </Reference>
        <Reference>
          <Citation>Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449-490.</Citation>
        </Reference>
        <Reference>
          <Citation>Helweg-Larsen K. The Danish register of causes of death. Scand J Public Health. 2011;39(7 Suppl):26-29.</Citation>
        </Reference>
        <Reference>
          <Citation>Hansen DL, Overgaard UM, Pedersen L, Frederiksen H. Positive predictive value of diagnosis coding for hemolytic anemias in the Danish national patient register. Clin Epidemiol. 2016;8:241-252.</Citation>
        </Reference>
        <Reference>
          <Citation>Heden KE, Jensen AO, Farkas DK, Norgaard M. Validity of a procedure to identify patients with chronic idiopathic thrombocytopenic purpura in the Danish national registry of patients. Clin Epidemiol. 2009;1:7-10.</Citation>
        </Reference>
        <Reference>
          <Citation>Mezaache S, Derumeaux H, Ferraro P, et al. Validation of an algorithm identifying incident primary immune thrombocytopenia in the French national health insurance database. Eur J Haematol. 2017;99(4):344-349.</Citation>
        </Reference>
        <Reference>
          <Citation>Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood. 1999;94(3):909-913.</Citation>
        </Reference>
        <Reference>
          <Citation>Latouche A, Allignol A, Beyersmann J, Labopin M, Fine JP. A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions. J Clin Epidemiol. 2013;66(6):648-653.</Citation>
        </Reference>
        <Reference>
          <Citation>Andersen PK, Geskus RB, de Witte T, Putter H. Competing risks in epidemiology: possibilities and pitfalls. Int J Epidemiol. 2012;41(3):861-870.</Citation>
        </Reference>
        <Reference>
          <Citation>Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses for competing risk data. Stat Med. 2017;36(27):4391-4400.</Citation>
        </Reference>
        <Reference>
          <Citation>Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509.</Citation>
        </Reference>
        <Reference>
          <Citation>Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676-682.</Citation>
        </Reference>
        <Reference>
          <Citation>Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130-1139.</Citation>
        </Reference>
        <Reference>
          <Citation>Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sorensen HT. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish national registry of patients. BMC Med Res Methodol. 2011;11:83.</Citation>
        </Reference>
        <Reference>
          <Citation>Stata Statistical Software: Release 15 [Computer Program]. College Station, TX: StataCorp LLC; 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Boyle S, White RH, Brunson A, Wun T. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. Blood. 2013;121(23):4782-4790.</Citation>
        </Reference>
        <Reference>
          <Citation>Jensen AO, Norgaard M, Engebjerg MC, et al. Predictors for splenectomy among patients with primary chronic immune thrombocytopenia: a population-based cohort study from Denmark. Ann Hematol. 2011;90(2):207-212.</Citation>
        </Reference>
        <Reference>
          <Citation>Thai LH, Mahevas M, Roudot-Thoraval F, et al. Long-term complications of splenectomy in adult immune thrombocytopenia. Medicine. 2016;95(48):e5098.</Citation>
        </Reference>
        <Reference>
          <Citation>Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med. 2002;347(12):911-920.</Citation>
        </Reference>
        <Reference>
          <Citation>Lohi S, Mustalahti K, Kaukinen K, et al. Increasing prevalence of coeliac disease over time. Aliment Pharmacol Ther. 2007;26(9):1217-1225.</Citation>
        </Reference>
        <Reference>
          <Citation>Norgaard M, Cetin K, Maegbaek ML, et al. Risk of arterial thrombotic and venous thromboembolic events in patients with primary chronic immune thrombocytopenia: a Scandinavian population-based cohort study. Br J Haematol. 2016;174(4):639-642.</Citation>
        </Reference>
        <Reference>
          <Citation>Ramagopalan SV, Wotton CJ, Handel AE, Yeates D, Goldacre MJ. Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC Med. 2011;9:1. https://doi.org/10.1186/1741-7015-9-1</Citation>
        </Reference>
        <Reference>
          <Citation>Yusuf HR, Hooper WC, Beckman MG, Zhang QC, Tsai J, Ortel TL. Risk of venous thromboembolism among hospitalizations of adults with selected autoimmune diseases. J Thromb Thrombolysis. 2014;38(3):306-313.</Citation>
        </Reference>
        <Reference>
          <Citation>Yusuf HR, Hooper WC, Grosse SD, Parker CS, Boulet SL, Ortel TL. Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: a study among a U.S. cohort of commercial insurance enrollees. Thromb Res. 2015;135(1):50-57.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
